Anti-amyloid antibody therapies in Alzheimer's disease
Open accessThe DOI matches its Crossref record; 39 of the 40 references it cites were found in a registry or an index, and 1 are not checked yet.
Abstract
After years of failed attempts to develop a disease-modifying therapy for Alzheimer’s disease, consistent evidence in support of clinical efficacy was finally presented for a monoclonal antibody targeting the amyloid-β protofibrils. In addition to meeting the primary outcome of slowing clinical disease progression over 18 months, secondary clinical outcomes and amyloid-β lowering on PET also underpin the positive results of the trial. In this opinion piece, we highlight the key characteristics of the previous unsuccessful trials and analyse the potential reasons why those attempts to develop a treatment for early Alzheimer’s disease failed. We compare the safety profiles of the different antibodies and highlight cautionary measures for their routine clinical use. Last, we discuss the role of blood-based biomarkers in transforming the clinical care pathway to facilitate the uptake of antibody treatments, proposing an integrated case-finding and treatment model crossing the different healthcare sectors. Taken together, a real breakthrough may have been achieved by proving that amyloid-β reduction results in clinical benefits, rather than just biomarker changes. At the same time, routine use of the new generation of drugs will show if statistical efficacy translates into clinically meaningful change. This may just be the beginning of a new era of Alzheimer’s disease drug development.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Clinical Dementia Rating (CDR): Current version and scoring rules
Morris, J. C. (1993) · Neurology · doi:10.1212/wnl.43.11.2412-a · Cited by 9,882
Lecanemab in early Alzheimer's disease
van Dyck, C. H., Swanson, C. J., Aisen, P., Bateman, R. J., Chen, C., Gee, M., Kanekiyo, M., Li, D., Reyderman, L., Cohen, S., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2212948 · Cited by 5,678
Self-citationThe antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., et al. (2016) · Nature · doi:10.1038/nature19323 · Cited by 3,059
Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Salloway, S., Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1304839 · Cited by 1,960
Overcoming the challenges in administering biopharmaceuticals: Formulation and delivery strategies
Mitragotri, S., Burke, P. A., & Langer, R. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4363 · Cited by 1,702
Palmqvist, S., Janelidze, S., Quiroz, Y. T., Zetterberg, H., Lopera, F., Stomrud, E., Su, Y., Chen, Y., Serrano, G. E., Leuzy, A., et al. (2020) · JAMA · doi:10.1001/jama.2020.12134 · Cited by 1,603
Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's Disease
Budd Haeberlein, S., Aisen, P. S., Barkhof, F., Chalkias, S., Chen, T., Cohen, S., Dent, G., Hansson, O., Harrison, K., von Hehn, C., et al. (2022) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2022.30 · Cited by 1,367
The 'Arctic' APP mutation (E693G) causes Alzheimer's disease by enhanced Aβ protofibril formation
Nilsberth, C., Westlind-Danielsson, A., Eckman, C. B., Condron, M. M., Axelman, K., Forsell, C., Stenh, C., Luthman, J., Teplow, D. B., Younkin, S. G., et al. (2001) · Nature Neuroscience · doi:10.1038/nn0901-887 · Cited by 1,209
CSF Biomarkers and Incipient Alzheimer Disease in Patients With Mild Cognitive Impairment
Mattsson, N. (2009) · JAMA · doi:10.1001/jama.2009.1064 · Cited by 1,176
Sperling, R. A., Jack, C. R., Black, S. E., Frosch, M. P., Greenberg, S. M., Hyman, B. T., Scheltens, P., Carrillo, M. C., Thies, W., Bednar, M. M., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.05.2351 · Cited by 857
Cited by
Items 101–182 of 182
Merkel, J., Perneczky, R., Jessen, F., Frölich, L., Jansen, O., Peters, S., Berg, D., Schulz, J. B., & Bartsch, T. (2026) · Alzheimer s Research & Therapy · doi:10.1186/s13195-026-02022-7 · Cited by 5
“…preference for protofibrils (lecanemab) or mono-/oligomers (solanezumab, cren-ezumab) but also demonstrate greater efficacy on plaque removal [2, 7, 26], while antibodies binding soluble Aβ, with the exception of lecanemab, failed to significantly reduce Aβ pathology in clinical trials [3, 27, 28].”
Self-citationFrederiksen, K. S., Morató, X., Zetterberg, H., Gauthier, S. G., Boada, M., Pytel, V., & Mattke, S. (2024) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0000000000000600 · Cited by 7
“…not only to determine the longer-term effectiveness and side effects of these amyloid plaque – reducing agents but also to explore combinations of drugs with different mechanisms of action, 17 since combination treatments will be important to enhance the clinical bene fi t achieved with monotherapy.”
BackgroundAlzheimer's disease drug development in an evolving therapeutic landscape
Weninger, S. C., Irizarry, M. C., Fleisher, A., León, T., Maruff, P. T., Miller, D. S., Assunção, S. S., Carrillo, M. C., & Weber, C. J. (2024) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.70015 · Cited by 6
“Across multiple Phase I–III trials, amyloid-targeting monoclonal antibodies have shown a dose-dependent reduction in amyloid plaque burden, 8 associated with slowing of cognitive and functional decline associated with the highest rates of amyloid clearance.”
Park, K., Lee, W. H., Cho, E., Kong, C. H., Min, H. S., Kim, M. S., Han, J. E., Jung, S. Y., Kim, D. H., & Ryu, J. H. (2025) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2025.119500 · Cited by 7
Neurological Disorders and Challenges in Their Theranostics
Kumar, P., Zelena, D., & Gautam, A. (2023) · Springer eBooks · doi:10.1007/978-981-99-9510-3_1 · Cited by 11
Gao, J., Li, W., Chen, N., Yi, Y., Wang, Z.-H., Chen, X., Zhao, Y., Yuan, Z., Gao, J., Pan, Y., et al. (2025) · Advanced Science · doi:10.1002/advs.202511611 · Cited by 7
The challenging concept of preclinical Alzheimer's disease
Wallon, D., & Garnier‐Crussard, A. (2025) · Revue Neurologique · doi:10.1016/j.neurol.2025.07.016 · Cited by 7
Trofinetide Improves Cognitive Function in APP/PS1 Mice by Suppressing Inflammation and Apoptosis
Chen, M., Ning, Y., Yang, H., & Jia, J. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-05500-5 · Cited by 5
Costa, A. C. S. (2024) · Brain Sciences · doi:10.3390/brainsci14111084 · Cited by 5
“Among the many editorials and review papers that chronicled this success story, a narrative review by Perneczky et al. [19] perfectly encapsulates the zeitgeist: “After years of failed attempts to develop a disease-modifying therapy for Alzheimer’s disease, consistent evidence in support of…”
Input of exome sequencing in early‐onset cerebral amyloid angiopathy
Grangeon, L., Charbonnier, C., Rousseau, S., Richard, A. C., Quenez, O., Zaréa, A., Boland, A., Olaso, R., Deleuze, J., CAA study group, et al. (2024) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.70027 · Cited by 4
Su, C.-H., Chang, Y., Tseng, H.-S., Kuo, C., Chen, J., Chien, P.-Y., Chang, Y.-J., & Hung, C. (2025) · Clinical Medicine · doi:10.1016/j.clinme.2025.100336 · Cited by 6
Alzheimer’s Disease: Treatment Today and Tomorrow
Gorthi, S. P., & Gupta, D. (2023) · Annals of Indian Academy of Neurology · doi:10.4103/aian.aian_254_23 · Cited by 5
“[39] Clinical deterioration as measured by the CRD‑SB was 27% slowed in the lecanemab group (‑0.45; P < 0.0001).”
InfluentialWisch, J. K., Kianfar, J., Carr, D. B., Dickerson, A. D., Vivoda, J. M., Harmon, A. C., Trani, J., Johnson, A. M., Doherty, J. M., Murphy, S. A., et al. (2023) · Transportation Research Part F Traffic Psychology and Behaviour · doi:10.1016/j.trf.2023.08.010 · Cited by 5
Combinatorial therapy in Alzheimer's disease
Giri, M. A., Kendre, P. N., Bhalke, R. D., Pande, V. V., Autade, K. A., & Sumbe, R. B. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13205-6.00026-1 · Cited by 7
Noguchi‐Shinohara, M., & Ono, K. (2024) · Internal Medicine · doi:10.2169/internalmedicine.4604-24 · Cited by 4
Collij, L. E., Bischof, G. N., Altomare, D., Bader, I., Battle, M. R., García, D. V., Alves, I. L., Wolz, R., Gismondi, R., Stephens, A. W., et al. (2024) · medRxiv · doi:10.1101/2024.05.22.24307653 · Cited by 4
Siddique, Y. H., Mantasha, I., Shahid, M., Jyoti, S., Rahul, & Varshney, H. (2023) · The Open Biology Journal · doi:10.2174/18741967-v11-e230704-2022-8 · Cited by 4
Kushwaha, N., Panjwani, D., Akarte, K., Patel, S., Ahlawat, P., Kesarla, R., Yadav, M. R., & Patel, A. (2025) · Current Nanoscience · doi:10.2174/0115734137361817250325071654 · Cited by 3
A comparison of multiple amyloid PET radiotracers for Down syndrome clinical trials
Zammit, M. D., Price, J. C., Christian, B. T., Rafii, M. S., Ances, B. M., Andrews, H., Bell, K. L., Birn, R. M., Brickman, A. M., Bulova, P. D., et al. (2025) · Brain Communications · doi:10.1093/braincomms/fcaf406 · Cited by 7
Cai, Q., Yang, Y., Yang, Y., Zhou, Y., Liu, Y., PeiyaoWu, Yang, F., Liu, J., & Liu, J. (2025) · Chemical Engineering Journal · doi:10.1016/j.cej.2025.168781 · Cited by 3
Sang, Z. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-23932-8.00035-2 · Cited by 3
Randomizing for Alzheimer’s disease drug trials should consider the cancer history of participants
Das, V., & Hajdúch, M. (2023) · Brain · doi:10.1093/brain/awad177 · Cited by 3
Rochais, C., Lecoutey, C., Lalut, J., Davis, A., Duval, E., Gaven, F., Largillière, S., Née, G., Corvaisier, S., Santos, J. S. O., et al. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116975 · Cited by 2
Modulation of antibody transport in the brain and spinal cord through the intranasal pathway
Spiegel, S., Joly, S., Meli, I., Chan, A., & Pernet, V. (2025) · Neurotherapeutics · doi:10.1016/j.neurot.2025.e00606 · Cited by 2
Peptides with Soft‐Aggregation Behavior Inhibit and Reverse Amyloid‐β Fibrillization
Liu, S., Peng, F., Liu, J., Wu, W., He, L., Cao, H., Liu, C., Qiu, F., & Zhang, W. (2025) · Small · doi:10.1002/smll.202505459 · Cited by 3
Kelley, R., Surr, C., Russell, G., Crowther, G. J. E., Dickinson, R., Dooley, J., Griffiths, A. W., Knapp, P., & Smith, S. J. (2025) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/08919887251362465 · Cited by 2
“22 An important in fl uencing factor as to whether a patient took dementia medication was how the risk and bene fi t information about drugs was presented, and for most participants the most in fl uential source of information was the clinician.”
InfluentialMarano, G., Cas, R. D., Ippoliti, I., Caffarra, P., Locuratolo, N., Vanacore, N., & Ancidoni, A. (2026) · Neurological Sciences · doi:10.1007/s10072-026-08829-4 · Cited by 2
Alzheimer’s Disease Prevention and Treatment Based on Population-Based Approaches
Perneczky, R. (2024) · Methods in molecular biology · doi:10.1007/978-1-0716-3774-6_2 · Cited by 2
Self-citationGao, Z., Zhu, W., Li, Y., Ye, W., Cheng, X. J., Zhou, S., Li, X., Li, X., Yu, Y., & Initiative, T. A. D. N. (2024) · Journal of Alzheimer s Disease · doi:10.1177/13872877241296130 · Cited by 4
“…lack of curative treatments, the available anti-amyloid-β (A β ) treatments (such as lecanemab, donanemab) have been achieved a real break-through, 6 thus early diagnosis is of great signi fi cance for timely intervention, which may help preserve cognition, improve patients ’ living ability and…”
Antibody-mediated clearance of an ER-resident aggregate that causes glaucoma
Thu, M., Qerqez, A. N., Hill, K. R., Azouz, L. R., Youngblood, H. A., Hill, S. E., Ku, Y., Peters, D. M. P., Maynard, J. A., & Lieberman, R. L. (2024) · PNAS Nexus · doi:10.1093/pnasnexus/pgae556 · Cited by 4
Agustini, D., Sabloak, R., Hasan, S., & Umar, T. P. (2025) · NeuroMarkers. · doi:10.1016/j.neumar.2025.100041 · Cited by 3
Morgan, C., Annegers, B., Taylor, M., Fox, S. S., & Titcomb, T. J. (2024) · European Journal of Neurology · doi:10.1111/ene.16294 · Cited by 1
“The recent suc - cesses of amyloid β targeted monoclonal antibodies suggest that the first disease-modifying therapies for AD may soon be available [26 ].”
BackgroundSacco, L., Morellini, L., & Cerami, C. (2023) · Frontiers in Neurology · doi:10.3389/fneur.2023.1162510 · Cited by 3
“Unfortunately, there is still poor high-quality evidence supporting an effective pharmacological treatment for MCI (34) and additional clinical trials are certainly needed to further investigate the efficacy and safety of these treatments (34).”
BackgroundRamaswamy, V. G., Ahirwar, M., Ryan, G., Signaevsky, M., Haroutunian, V. H., & Finkbeiner, S. M. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.05.19.541376 · Cited by 3
Koo, J., Lee, H. S., Choi, Y. S., Baik, K., Park, M., & Initiative, A. D. N. (2026) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2026.1724274 · Cited by 1
Kawaguchi, Y., Tamemoto, N., Uehata, Y., Miyazaki, Y., Shinoda, W., & Futaki, S. (2025) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.c25-00479 · Cited by 3
Ma, M., Wang, J., Zhong, W., Li, Z., & Zhao, Y. (2025) · Angewandte Chemie · doi:10.1002/ange.202517917 · Cited by 1
Hwang, H., Park, D., & Kim, J. (2026) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-025-01982-1 · Cited by 1
“Thus, many efforts have been dedicated to cure the AD through controlling the amyloid-β accumulation with various measures [ 3, 4, 8].”
Anti-amyloid antibody therapies for Alzheimer's disease: how much do we really understand?
Chen, Y. (2026) · Targetome · doi:10.48130/targetome-0026-0004 · Cited by 1
Structure-guided design and synthesis of selective butyrylcholinesterase inhibitors
Law, C. S. W., Ha, Z. Y., Brazzolotto, X., & Yeong, K. Y. (2026) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2026.145611 · Cited by 1
Early-life neighborhood resources and later-life cognitive function
Farmer, J. G., Tang, I. W., James, P., Kubzansky, L. D., Mukherjee, R., Hickman, R. C., Kessler, W., Germine, L. T., & Weisskopf, M. G. (2026) · Environmental Research · doi:10.1016/j.envres.2026.124257 · Cited by 2
Coles, M., Porto, R. R., Chesworth, R., Steiner-Lim, G. Z., & Karl, T. (2026) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2026.04.003 · Cited by 2
Progress and challenges in drug delivery for the treatment of Alzheimer’s disease
Haghighi, F. H., Xie, J., Ebert, E., & Siahaan, T. J. (2026) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2026.2663114 · Cited by 1
“Clinical outcomes are strongly influenced by target selection (e.g. soluble vs. fibrillar Aβ), disease-stage mismatch, and the possibility that amyloid removal is insufficient once downstream neurodegeneration is established [36].”
Wang, Y., Song, W., Yang, X., Meng, W., Ma, Y., Wang, A., Guo, G., Zhang, Z., Li, Z., Han, H., et al. (2026) · BMC Medical Imaging · doi:10.1186/s12880-026-02404-1 · Cited by 1
“Alzheimer’s disease (AD) is a progressive neurodegenerative disorder and the most common cause of dementia worldwide, characterized by progressive cognitive decline and irreversible functional impairment [1, 2].”
Developments in the design and therapeutic applications of GSK3β inhibitors
Daoud, S., & Taha, M. O. (2026) · Future Medicinal Chemistry · doi:10.1080/17568919.2026.2675873 · Cited by 1
Kuzman, D., Klančnik, U., Grum, E., & Derganc, J. (2023) · Pharmaceuticals · doi:10.3390/ph16071002 · Cited by 1
“With more than 100 FDA-approved mAb products as of 2021 and ongoing research into new targets such as Alzheimer’s disease [2], the field continues to expand.”
BackgroundA head-to-head comparison of multiple amyloid PET radiotracers for Down syndrome clinical trialsPreprint
Zammit, M. D., Price, J. C., Christian, B., & Rafii, M. S. (2025) · medRxiv · doi:10.1101/2025.03.18.25324200 · Cited by 1
“Clinical trials in neurotypical populations during early-stage dementia have shown the success of anti-amyloid therapies at removing A and slowing the progression of clinical symptoms 7 .”
Lobos, P., More, J., Bruna, B., & Antonello Penna, S. (2023) · Revista Hospital Clínico Universidad de Chile · doi:10.5354/2735-7996.2023.71414
“En conjunto, el análisis de todos los ensayos con los principales anticuerpos anti-amiloide indican una relación entre el nivel de reducción de Aβ (determinación por PET) y los beneficios clínicos evaluados mediante la escala CDR-SB, lo que sugiere que efectivamente la reducción de Aβ puede en alguna medida lograr alt…”
BackgroundThe ubiquitin-proteasome system in neurodegenerative diseases: Lessons from mutant ubiquitin
Verheijen, L. (2023) · Research Publications (Maastricht University) · doi:10.26481/dis.20231024lv · Cited by 1
Ethical Aspects in Diagnostics, Prediction, and Treatment of Dementia
Rostamzadeh, A., Radenbach, K., & Jessen, F. (2023) · GeroPsych · doi:10.1024/1662-9647/a000326
Self-citationSharma, A., & Ewald, C. Y. (2023) · PubMed Central · doi:10.17912/micropub.biology.000907
Der monoklonale Antikörper Gantenerumab bei früher Alzheimer-Krankheit
Perneczky, R., (DNG), A. N. T. D. D. N. G., & Nitschmann, S. (2024) · Die Innere Medizin · doi:10.1007/s00108-024-01695-2
Self-citationMidlife is good for more than a crisis: Exercise for dementia prevention
Fenton, L. E., & Pa, J. (2024) · Journal of the American Geriatrics Society · doi:10.1111/jgs.19207
The Contribution of the Renin-Angiotensin System to Alzheimer’s Disease
Güzel, Ö., & Kehoe, P. G. (2024) · Current topics in behavioral neurosciences · doi:10.1007/7854_2024_525 · Cited by 1
Functional Proteins/Peptides Targeting to Clear Amyloid‐β for Alzheimer's Disease Therapy
Gao, Z., Hou, R., & Qian, C. (2025) · ChemBioChem · doi:10.1002/cbic.202400912
James, T., Zhao, L., Xu, H., Wu, J., Schweidel, D. A., Goldstein, F. C., Levey, A. I., Qiu, D., Loring, D. W., Hanfelt, J., et al. (2025) · medRxiv · doi:10.1101/2025.06.27.25330448
Alzheimer's Disease: New PerspectivesPreprint
McCaulley, M. E. (2025) · Preprints.org · doi:10.20944/preprints202507.0478.v1
Cai, Q., Yang, Y., Wang, L., Zhou, Y., Liu, Y., Wu, P., Yang, F., Liu, Y., & Liu, J. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5350839
Early-Life Neighborhood Resources and Later-Life Cognitive FunctionPreprint
Farmer, J. G., Tang, I. W., James, P., Kubzansky, L. D., Mukherjee, R., Hickman, R. C., Kessler, W., Germine, L. T., & Weisskopf, M. G. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5788032
Trares, K., Wiesenfarth, M., Stocker, H. R., Perna, L., Petrera, A., Hauck, S. M., Beyreuther, K., Brenner, H., & Schöttker, B. (2024) · Figshare · doi:10.6084/m9.figshare.26701588
Zafar, I., Khan, M. S., Jamal, A., Shafiq, S., Bahwerth, F. S., & Khan, N. U. (2025) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2025.104070 · Cited by 2
Terry, G., Aziz, S., Raihana, N., Xie, L., Rockwell, P., Serrano, P. A., & Figueiredo-Pereira, M. E. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.01.17.700104
Rochais, C., Lecoutey, C., Culley, G. R., Curel, T., Davis, A., Duval, E., Rouvière, L., Henriques, A., Legrand, R., Claeysen, S., et al. (2026) · Journal of Alzheimer s Disease · doi:10.1177/13872877261424925
Microstates to modulation: EEG signatures guiding clinical translation in dementia
Noda, Y. (2026) · Clinical Neurophysiology · doi:10.1016/j.clinph.2026.2111876
Visual memory correlates with AD biomarkers in cognitively unimpaired individuals
James, T., Zhao, L., Xu, H., Wu, J., Schweidel, D. A., Goldstein, F. C., Levey, A. I., Qiu, D., Loring, D. W., Hanfelt, J., et al. (2026) · Alzheimer s & Dementia · doi:10.1002/alz.71417
“4 Recognizing the need for earlier interventions, research has increasingly focused on identifying biomarkers and imaging techniques capable of detecting AD pathology in the asymptomatic phase, allowing for interventions that could delay or prevent clinical disease.”
Kiani, I., Hajiasadi, E., Torkamani, Z. T., Bagherzadeh, Y., Abbasifar, P., Zare, A. K., Moqadam, A. H. M., Mohammadzadeh, S., Kakadiya, J., Khosravi, B., et al. (2026) · European Journal of Radiology Artificial Intelligence · doi:10.1016/j.ejrai.2026.100094 · Cited by 1
Wang, D., Yan, S., Zhou, R., Li, Y., Liu, L., Wei, Y., Wang, D., Yao, H., Zhou, B., Lu, J., et al. (2026) · Science Advances · doi:10.1126/sciadv.aef3787
Alia, A. O., Urquhart, K., Carson, H., Killinger, B. A., Janson, C., & Romanova, L. Y. (2026) · Acta Neuropathologica Communications · doi:10.64898/2026.05.13.724866
Hsu, J., Huang, S.-Y., Wu, H.-C., Lin, K., Huang, K., Huang, C.-C., Kim, S., & Hsiao, I. (2026) · Alzheimer s Research & Therapy · doi:10.1186/s13195-026-02083-8
MRI-Based Alzheimer's Disease Classification Using TensorFlow and Deep Learning
Nagendrababu, N. C., Muniraju, M., & Varadaraju, H. R. (2026) · International Conference on Knowledge Engineering and Communication Systems (ICKECS) · doi:10.1109/ickecs70176.2026.11528037
Saunders, S., Haider, F., Lanzi, A. M., MacWhinney, B., Fromm, D., Chou, C., Liu, Y., Chang, Y., Gregory, S., Ritchie, C. W., et al. (2026) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.70341 · Cited by 1
“18 Onthesegrounds, speech biomarkers appear to be a critical component in addressing the multifaceted challenges in managing ADRD.”
Features predicting data exclusion in imaging studies of Alzheimer's disease
Flores, S. E., Scott, J., Lu, R., Su, Y., Keefe, S., Smith, T. H., Hornbeck, R. C., McKay, N. S., Strain, J. F., Simmons, A., et al. (2026) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.70389
Ersoezlue, E., Preis, L., Aktuz, A., Droste, L., Erman, A., Gref, D., Strentz, K. S., & Hellmann‐Regen, J. (2026) · The Journal of Prevention of Alzheimer s Disease · doi:10.1016/j.tjpad.2026.100630
“The clinical introduction of disease-modifying anti-amyloid monoclonal antibodies has shifted the focus of dementia assessment toward early and precisely defined disease stages [1,2].”
Kim, S., Oda, H., Oyama, R., Makishi, R., Bade, S., Bade, S., Ally, I., Iijima, Y., Gibo, Y., Minami, K., et al. (2026) · BJPsych Open · doi:10.1192/bjo.2026.12044
MRI-free amyloid PET quantification using a deep learning model and white matter reference
Shin, S., Mo, Y., Hwang, H. S., Lee, M., Lee, J. J., Kim, C., & Choi, H. J. (2026) · Journal of Alzheimer s Disease · doi:10.1177/13872877261470021
Advancing Strain‐Specific Immunotherapy for Alzheimer's Disease and Tauopathies
Priya, E. S., Vasanth, S., Taj, T., Ameen, M. P. M., Danam, S. S., & Kumar, M. V. (2026) · Wiley eBooks · doi:10.1002/9781394336241.ch3
Small nucleolar RNAs: Emerging therapeutic and diagnostic frontiers in Alzheimer’s disease
Sharma, T., Sharma, P., Bashir, B., Singh, S. K., & Vishwas, S. (2026) · Drug Discovery Today · doi:10.1016/j.drudis.2026.104771
Frölich, L., Hausner, L., & Schneider, F. (2026) · Springer eBooks · doi:10.1007/978-3-662-70668-8_34
Nimbalkar, J., & Shinde, R. (2026) · Journal of Natural Medicines · doi:10.1007/s11418-026-02090-x
Frommann, I., Vogel, S., Jansén, L., Meiberth, D. U., Schild, A., Jessen, F., Zank, S., Schneider, A., McCormick, C., & Wagner, M. (2026) · Journal of Alzheimer s Disease · doi:10.1177/13872877261490478
Self-citation
Metadata
- Authors
- Perneczky, R., Jessen, F., Grimmer, T., Levin, J., Flöel, A., Peters, O., & Froelich, L.
- Affiliations
- German Center for Neurodegenerative Diseases (DE)
- University of Cologne (DE)
- TUM Klinikum (DE)
- Universitätsmedizin Greifswald (DE)
- Central Institute of Mental Health (DE)
- Corresponding author
- Perneczky, Robert
- ORCID
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2023-01-19
- Volume
- 146
- Issue
- 3
- Pages
- 842-849
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- OpenAlex
- W4317401758
- Cited by
- 182
- References
- 40
- Citations by year
- 2026: 33 · 2025: 50 · 2024: 57 · 2023: 42
- FWCI
- 32.13
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Brain (publishedVersion)
- PubMed (publishedVersion)
- Open access LMU (Ludwid Maxmilian's Universitat Munchen) (submittedVersion)
- mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich) (submittedVersion)
- DZNE Pub (submittedVersion)
- Funders
- Deutsche Forschungsgemeinschaft
- VERUM Foundation
- Sheffield National Institute for Health Research
- Biomedical Research Centre
- University of Cambridge—Ludwig-Maximilians-University Munich Strategic Partnership
- Hector II Foundation
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- Alzheimer's disease, anti-amyloid monoclonal antibodies, amyloid-beta protofibrils, amyloid PET, disease-modifying therapy, clinical trial failure, antibody safety, blood-based biomarkers, case finding, early Alzheimer's disease
- MeSH terms
- Alzheimer Disease, Amyloid, Antibodies, Monoclonal, Humans, Biomarkers, Amyloid beta-Peptides, Treatment Outcome, Disease Progression, Cognitive Dysfunction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.